We report a 19-year-old female with systemic lupus erythematosus and lupus nephritis who developed pulmonary hemorrhage (PH) refractory to conventional immunosuppressive treatment. She was initially treated with intravenous methylprednisolone and cyclophosphamide pulses. She required mechanical ventilation due to a lack of responsiveness and her disease was considered refractory to conventional treatment. Rituximab was administered and this was followed by clinical improvement in both PH and nephritis. Rituximab may be a useful therapeutic option for the treatment of refractory PH.

Keywords:
Pulmonary hemorrhage, Lupus, Rituximab, Vasculitis
1.
Piastraa M, Ruggiero A, Langer A, et al: Pulmonary hemorrhage complicating a typical hemolytic-uremic syndrome. Respiration 2004;71:537–541.
2.
Rutherford RM, O’Keeffe D, Gilmartin JJ: An unusual case of non-specific interstitial pneumonitis. Respiration 2004;71:202–205.
3.
Hoshi K, Matsuda M, Ishikawa M, et al: Successful treatment of fulminant pulmonary hemorrhage associated with systemic lupus erythematosus. Clin Rheumatol 2004;23:252–255.
4.
Erickson RW, Franklin WA, Emlen W, et al: Treatment of hemorrhagic lupus pneumonitis with plasmapheresis. Semin Arthritis Rheum 1994;24:114–123.
5.
Silverman GJ: Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthritis Rheum 2005;52:371–377.
6.
Armstrong DJ, Wright SA, Finch MB, et al: Active systemic lupus erythematosus successfully treated with rituximab and oral steroids. Clin Exp Rheumatol 2004;22:787–788.
7.
Cragg MS, Walshe CA, Ivanov AO, et al: The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140–174.
8.
Wu CY, Chiou YH, Chiu PC, Hsieh KS: Severe pulmonary hemorrhage as the initial manifestation in systemic lupus erythematosus with active nephritis. Lupus 2001;10:879–882.
9.
Lee JG, Joo KW, Chung WK, Jung YC, Zheung SH, Yoon HJ, et al: Diffuse alveolar hemorrhage in lupus nephritis. Clin Nephrol 2001;55:282–288.
10.
Santos-Ocampo AS, Mandell BF, Fessler BJ: Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest 2000;118:1083–1090.
11.
Liu MF, Lee JH, Weng TH, Lee YY: Clinical experience of 13 cases with severe pulmonary hemorrhage in systemic lupus erythematosus with active nephritis. Scand J Rheumatol 1998;27:291–295.
12.
Barile JA, Jara LJ, Medina-Rodríguez F, et al: Pulmonary hemorrhage in systemic lupus erythematosus. Lupus 1997;6:445–448.
13.
Looney RJ, Anolik J, Sanz I: Treatment of SLE with anti-CD20 monoclonal antibody. Curr Dir Autoimmun 2005;8:193–195.
14.
Walsh M, Jayne D: Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int 2007;72:676–682.
15.
Cacoub P, Saadoun D: Hepatitis C virus infection induced vasculitis. Clin Rev Allergy Immunol 2008;35:30–39.
16.
Heresi GA, Farver CF, Stoller JK: Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab. Case report and review of the literature. Respiration 2008; 76:449–453.
17.
Camus P, Fanton A, Bonniaud P, et al: Interstitial lung disease induced by drugs and radiation. Respiration 2004;71:301–326.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.